Cardiac myocyte follistatin-like 1 functions to attenuate hypertrophy following pressure overload

• Published in: Proceedings of the National Academy of Sciences - PNAS 2011-10, Vol.108 (43), p.E899-E906
• Main Authors: Shimano, Masayuki, Ouchi, Noriyuki, Nakamura, Kazuto, van Wijk, Bram, Ohashi, Koji, Asaumi, Yasuhide, Higuchi, Akiko, Pimentel, David R, Sam, Flora, Murohara, Toyoaki, van den Hoff, Maurice J. B, Walsh, Kenneth
• Format: Article
• Language: English
• Subjects: AMP-activated protein kinase; Analysis of Variance; Animals; Biological Sciences; Blotting, Western; Cardiomegaly - metabolism; Cardiomyocytes; DNA Primers - genetics; Echocardiography; Follistatin-Related Proteins - genetics; Follistatin-Related Proteins - metabolism; Glycoproteins; Heart; heart failure; Homeostasis; hypertrophy; Mice; Mice, Knockout; Myocytes, Cardiac - metabolism; phenotype; PNAS Plus; Pressure; Real-Time Polymerase Chain Reaction; Rodents; Signal Transduction - physiology; Statistics, Nonparametric; Ventricular Remodeling - genetics; Ventricular Remodeling - physiology
• ISSN: 0027-8424; 1091-6490
• DOI: 10.1073/pnas.1108559108

Factors secreted by the heart, referred to as "cardiokines," have diverse actions in the maintenance of cardiac homeostasis and remodeling. Follistatin-like 1 (Fstl1) is a secreted glycoprotein expressed in the adult heart and is induced in response to injurious conditions that promote myocardial hypertrophy and heart failure. The aim of this study was to investigate the role of cardiac Fstl1 in the remodeling response to pressure overload. Cardiac myocyte-specific Fstl1-KO mice were constructed and subjected to pressure overload induced by transverse aortic constriction (TAC). Although Fstl1-KO mice displayed no detectable baseline phenotype, TAC led to enhanced cardiac hypertrophic growth and a pronounced loss in ventricular performance by 4 wk compared with control mice. Conversely, mice that acutely or chronically overexpressed Fstl1 were resistant to pressure overload-induced hypertrophy and cardiac failure. Fstl1-deficient mice displayed a reduction in TAC-induced AMP-activated protein kinase (AMPK) activation in heart, whereas Fstl1 overexpression led to increased myocardial AMPK activation under these conditions. In cultured neonatal cardiomyocytes, administration of Fstl1 promoted AMPK activation and antagonized phenylephrine-induced hypertrophy. Inhibition of AMPK attenuated the antihypertrophic effect of Fstl1 treatment. These results document that cardiac Fstl1 functions as an autocrine/paracrine regulatory factor that antagonizes myocyte hypertrophic growth and the loss of ventricular performance in response to pressure overload, possibly through a mechanism involving the activation of the AMPK signaling axis.